Citadel Advisors’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Citadel Advisors’s Portfolio OCRX Stock Details OCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-55,673	Closed	-$73K	–	8486
2017 Q1	$73K	Buy	+55,673	New	+$70.9K	﹤0.01%	6959
2016 Q1	–	Sell	-18,932	Closed	-$59K	–	8768
2015 Q4	$59K	Buy	+18,932	New	+$64.7K	﹤0.01%	7175
2015 Q3	–	Sell	-10,082	Closed	-$38K	–	9468
2015 Q2	$38K	Buy	+10,082	New	+$38.7K	﹤0.01%	7848
2014 Q2	–	Sell	-14,205	Closed	-$150K	–	8541
2014 Q1	$150K	Buy	+14,205	New	+$203K	﹤0.01%	5797
2013 Q3	–	Sell	-2,149	Closed	-$12K	–	6986
2013 Q2	$12K	Buy	+2,149	New	+$13.4K	﹤0.01%	6202

Other funds holding OCRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's OCRX Position: Q2 2017 in Review

Citadel Advisors sold out of Ocera Therapeutics, Inc. (OCRX) in Q2 2017, closing a stake of 55,673 shares — an estimated $73K sold.

Citadel Advisors first reported a position in OCRX in Q2 2013 and held it in 5 quarters. The position peaked at $150K in Q1 2014. 24 funds tracked by Wall St. Rank hold OCRX as of Q2 2017.

Citadel Advisors reported no remaining Ocera Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Citadel Advisors sold 55,673 Ocera Therapeutics, Inc. shares in Q2 2017, an estimated $73K.
Citadel Advisors first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
Citadel Advisors's Ocera Therapeutics, Inc. position peaked at $150K in Q1 2014.
24 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q2 2017.

Based on Citadel Advisors's 13F filing for Q2 2017, filed 11 Aug 2017.